Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
0.892
0.00 (0.03%)
At close: Jan 17, 2025, 4:00 PM
0.936
+0.044 (4.92%)
Pre-market: Jan 21, 2025, 9:00 AM EST
Nektar Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Nektar Therapeutics stock have an average target of 4.50, with a low estimate of 1.00 and a high estimate of 7.00. The average target predicts an increase of 404.48% from the current stock price of 0.89.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NKTR stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 1 | 3 |
| Buy | 1 | 1 | 1 | 2 | 2 | 1 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6.5 | Strong Buy | Reiterates | $6.5 | +628.70% | Jan 13, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +348.43% | Jan 8, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $7 | Buy | Initiates | $7 | +684.75% | Nov 4, 2024 |
| BTIG | BTIG | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +348.43% | Sep 30, 2024 |
| Jefferies | Jefferies | Hold Maintains $0.5 → $1 | Hold | Maintains | $0.5 → $1 | +12.11% | Mar 6, 2024 |
Financial Forecast
Revenue This Year
101.70M
from 90.12M
Increased by 12.85%
Revenue Next Year
90.11M
from 101.70M
Decreased by -11.40%
EPS This Year
-0.77
from -1.45
EPS Next Year
-0.79
from -0.77
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 143.8M | 136.6M | 135.1M | |||
| Avg | 101.7M | 90.1M | 89.7M | |||
| Low | 85.1M | 61.2M | 55.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 59.5% | 34.3% | 49.9% | |||
| Avg | 12.8% | -11.4% | -0.5% | |||
| Low | -5.6% | -39.8% | -38.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.61 | -0.67 | -0.42 |
| Avg | -0.77 | -0.79 | -0.72 |
| Low | -0.81 | -0.96 | -0.91 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.